Form 4: Regeneron EVP Marion McCourt Sells 250 Shares Under 10b5-1 Plan

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, sold 250 shares of common stock on May 1, 2024, at a price of $889.41 per share, according to a Form 4 filing with the SEC.

Summary

• Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, sold 250 shares of common stock on May 1, 2024.
• The sale was executed at a price of $889.41 per share.
• The transaction was made pursuant to a pre-arranged trading plan under Rule 10b5-1(c), adopted on February 16, 2023.
• Following the transaction, McCourt directly owns 12,931 shares of Regeneron common stock.
• McCourt also indirectly owns 174 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to an executive's stock sale under a pre-arranged trading plan. It doesn't convey any particularly positive or negative sentiment.

Industry Context

Sales by company executives are a normal part of corporate activity. Investors often look at the overall trend of insider transactions to gauge sentiment. A pre-arranged 10b5-1 trading plan suggests the sale was planned well in advance.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but the pre-arranged nature of the sale mitigates potential concerns.

Key Dates